Search

everythinglearnresearchcommunity

for

Search:↓

Prostate cancer cells can make their own androgens to activate the androgen receptor, and treatments like abiraterone may increase this ability, suggesting new therapies should target the entire steroid-making pathway.

Mutations in certain receptors can cause diseases and offer new treatment options.

New androgen receptor modulators show promise for treating diseases like prostate cancer and muscle wasting.

The androgen receptor's shape-changing ability helps it function but can lead to cancer treatment resistance.

Dutasteride and finasteride affect different cell types differently.

Finasteride may improve prostate cancer treatment outcomes.

NcoA4 may have roles beyond helping control gene activity, possibly affecting cell behavior and stability.

New treatments for prostate cancer are less toxic and show promise, but more research is needed to enhance their effectiveness and reduce side effects.

Analog 23 is a promising compound for prostate cancer treatment.

Certain changes to the B-ring of androgen receptor ligands can increase their effectiveness for potential treatments of muscle and bone conditions.

Researchers found new potential treatments for conditions related to the androgen receptor, like male hormonal contraception, by testing thousands of compounds.

Different substances that activate or block the androgen receptor can affect male development and treat conditions like prostate cancer.

ERG increases SOX9, promoting prostate cancer growth and invasion.

Minoxidil can reduce functions related to androgen receptors.

New treatments targeting androgen receptors show promise for drug-resistant prostate cancer.

Too much AKR1C3 enzyme causes resistance to finasteride by increasing testosterone.

New steroid compounds may help with hormonal therapy and have potential benefits for glucose disorders, but more research is needed.

Targeting androgen receptors shows promise for treating triple-negative breast cancer, but more research is needed.

New treatments for prostate cancer and BPH show promise, including novel compounds that target hormone synthesis and response.

Different drugs can treat high male hormone levels in women, but they have various effects and some may harm a fetus.

Scientists made the first metal-based compounds from a nonsteroidal antiandrogen drug, which showed potential in fighting both hormone-dependent and independent prostate cancer cells.

Don't combine abiraterone and spironolactone for prostate cancer treatment as it may worsen the disease.

Androgens and SARMs play a role in body mass, frailty, skin health, and hair growth, and are used in treating prostate cancer, acne, and hair loss, with potential for new uses and improved versions in the future.

PROTACs offer new ways to treat hard-to-target diseases, with promising drugs for cancer in advanced trials.

A new compound, 3a, effectively fights prostate cancer better than finasteride.

PROTAC technology shows promise for cancer treatment but needs more effective E3 ligase recruiters.

A new mutation in the human glucocorticoid receptor reduces its function and causes resistance to glucocorticoids.

A mutation in the KRT25 gene causes woolly hair and hair loss.

Two new mutations in the AR gene linked to severe androgen insensitivity were found.

Mutations in the AR gene cause hair thinning and loss.